This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Vifor Pharma Past Earnings Performance
Past criteria checks 4/6
Key information
16.3%
Earnings growth rate
16.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 7.5% |
| Return on equity | 6.7% |
| Net Margin | 8.1% |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Vifor Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 1,812 | 147 | 544 | 225 |
| 30 Jun 21 | 1,753 | 213 | 542 | 155 |
| 31 Mar 21 | 1,757 | 176 | 551 | 175 |
| 31 Dec 20 | 1,762 | 139 | 560 | 194 |
| 30 Jun 20 | 1,709 | 93 | 553 | 249 |
| 31 Mar 20 | 1,732 | 101 | 563 | 231 |
| 31 Dec 19 | 1,754 | 108 | 573 | 212 |
| 30 Sep 19 | 1,845 | 129 | 588 | 226 |
| 30 Jun 19 | 1,784 | 100 | 576 | 224 |
| 31 Mar 19 | 1,711 | 126 | 571 | 215 |
| 31 Dec 18 | 1,639 | 152 | 567 | 206 |
| 30 Sep 18 | 1,571 | 157 | 571 | 199 |
| 30 Jun 18 | 1,504 | 162 | 576 | 191 |
| 31 Mar 18 | 1,441 | 98 | 561 | 188 |
| 31 Dec 17 | 1,378 | 34 | 546 | 185 |
| 30 Sep 17 | 1,345 | 26 | 544 | 173 |
| 30 Jun 17 | 1,312 | 18 | 543 | 162 |
| 31 Mar 17 | 1,283 | 82 | 503 | 142 |
| 31 Dec 16 | 1,254 | 147 | 464 | 122 |
| 30 Sep 16 | 1,944 | 218 | 525 | 84 |
| 30 Jun 16 | 2,635 | 290 | 587 | 46 |
| 31 Mar 16 | 3,265 | 295 | 654 | 23 |
| 31 Dec 15 | 3,896 | 301 | 722 | 0 |
Quality Earnings: 0RPD has high quality earnings.
Growing Profit Margin: 0RPD's current net profit margins (8.1%) are higher than last year (7.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RPD's earnings have grown by 16.3% per year over the past 5 years.
Accelerating Growth: 0RPD's earnings growth over the past year (5.7%) is below its 5-year average (16.3% per year).
Earnings vs Industry: 0RPD earnings growth over the past year (5.7%) exceeded the Pharmaceuticals industry 5.6%.
Return on Equity
High ROE: 0RPD's Return on Equity (6.7%) is considered low.